



(51) International Patent Classification:

Not classified

(21) International Application Number:

PCT/IB2018/058514

(22) International Filing Date:

30 October 2018 (30.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/579,186 31 October 2017 (31.10.2017) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **PECHENOV, Sergei**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **TYAGI, Puneet**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **SUBRAMONY, Janardhanan Anand**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **OYLOE, Jacob**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGS

(57) Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.



From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

COOK, Andrew
MedImmune Limited
Milstein Building, Granta Park
Cambridge, UK CB21 6GH
ROYAUME-UNI

Date of mailing (day/month/year) 06 April 2020 (06.04.2020)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference ORPEP200WOPC	
International application No. PCT/IB2018/058514	International filing date (day/month/year) 30 October 2018 (30.10.2018)

1. The following indications appeared on record concerning:		
☒ the applicant	☐ the inventor	☐ the agent
☐ the common representative		
Name and Address MEDIMMUNE, LLC One Medimmune Way Gaithersburg, Maryland 20878 United States of America	State of Nationality US	State of Residence US
	Telephone No. 301-398-0000	
	Facsimile No. 301-398-9306	
	E-mail address patents@astrazeneca.com	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
☒ the person	☐ the name	☐ the address
☐ the nationality		
☐ the residence		
Name and Address MEDIMMUNE LIMITED Milstein Building, Granta Park Cambridge CB21 6GH United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No. 301-398-0000	
	Facsimile No. 301-398-9306	
	E-mail address patents@astrazeneca.com	
☒ Notifications by e-mail authorized		
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
☐ the receiving Office	☐ the International Preliminary Examining Authority	
☐ the International Searching Authority	☒ the designated Offices concerned	
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned	
	☐ other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Bellour Veronique e-mail ro.ib@wipo.int Telephone No. +4122 338 8602
---	---